low - Pre-revenue biotech with no direct GDP linkage. Clinical trial timelines and FDA processes are largely insulated from economic cycles. However, severe recessions can impact: (1) ability to raise capital as risk appetite declines, (2) hospital/site participation in trials during healthcare system stress, and (3) future reimbursement environment if approved during downturn.

Rising rates negatively impact valuation through higher discount rates applied to distant future cash flows (NPV of potential product revenues 5-10 years out declines significantly). Higher rates also increase cost of capital for future financing rounds and reduce investor appetite for speculative, cash-burning biotechs as safer fixed-income yields become attractive. The 1.6x P/B and 693x P/S multiples compress materially in rising rate environments. Additionally, cash held on balance sheet earns higher returns in rising rate environment (minor positive offset).

growth - Attracts speculative biotech investors seeking asymmetric risk/reward from binary clinical catalysts. Typical holders include specialized healthcare hedge funds, biotech-focused venture investors, and retail traders betting on FDA approval lottery tickets. Not suitable for value or income investors given zero revenue, negative cash flow, and no dividend. The -12.6% 1-year return but +21.9% 3-month return suggests event-driven volatility around clinical updates.